Skip to main content
VCbacked
Log inGet Started

Hermes Biosciences

San Francisco, United States

Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.

$6.0M raised
Nov 2025
Seed
BiotechnologyMedicalPharmaceutical

Top Investors

Paladin Capital GroupVertical Venture PartnersGenoa Ventures

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Hermes Biosciences

How much funding has Hermes Biosciences raised?
Hermes Biosciences has raised $6.0M in total funding. The most recent round was Seed. The last funding was announced in November 2025.
Who are Hermes Biosciences's investors?
Hermes Biosciences's investors include Paladin Capital Group, Vertical Venture Partners, Genoa Ventures.
Where is Hermes Biosciences headquartered?
Hermes Biosciences is headquartered in San Francisco, United States.
What does Hermes Biosciences do?
Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.
What stage is Hermes Biosciences at?
Hermes Biosciences is at the Seed stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Hermes Biosciences — Funding & Investors." VCBacked, November 18, 2025, https://www.vcbacked.co/company/hermes-biosciences. Accessed June 17, 2026.
APA
VCBacked. (2025). Hermes Biosciences — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/hermes-biosciences
Wikipedia (cite web)
{{cite web |title=Hermes Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/hermes-biosciences |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong